[1]
Abou-Seif MA,
Youssef AA. Evaluation of some biochemical changes in diabetic patients.
Clin Chim Acta 2004; 346(2): 161-70.
[2]
Santaguida PL,
Balion C,
Hunt D,
Morrison K,
Gerstein H,
Raina P,
Booker L,
Yazdi H. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose.
Evid Rep Technol Assess (Summ) 2005; (128): 1-11.
[3]
Chen X,
Yang L,
Zhai SD. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.
Chin Med J (Engl) 2012; 125(23): 4301-6.
[4]
Barthelemy O,
Jacqueminet S,
Rouzet F,
Isnard R,
Bouzamondo A,
Le Guludec D,
Grimaldi A,
Metzger JP,
Le Feuvre C. Intensive cardiovascular risk factors therapy and prevalence of silent myocardial ischaemia in patients with type 2 diabetes.
Arch Cardiovasc Dis 2008; 101(9): 539-46.
[5]
Adler AI. UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes.
Diabet Med 2008; 25 Suppl 2: 41-6.
[6]
Hess K,
Grant PJ. Inflammation and thrombosis in diabetes.
Thromb Haemost 2011; 105 Suppl 1: S43-54.
[7]
Thrainsdottir IS,
Aspelund T,
Thorgeirsson G,
Gudnason V,
Hardarson T,
Malmberg K,
Sigurdsson G,
Rydén L. The association between glucose abnormalities and heart failure in the population-based Reykjavik study.
Diabetes Care 2005; 28(3): 612-6.
[8]
Golubnitschaja O,
Yeghiazaryan K,
Skowasch D,
Schild H,
Bauriedel G. p21WAF1/CIP1 and 14-3-3 sigma gene expression in degenerated aortic valves: a link between cell cycle checkpoints and calcification.
Amino Acids 2006; 31(3): 309-16.
[9]
Newby AC,
Johnson JL. Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability.
Circ Res 2005; 97(10): 958-60.
[10]
Kelly-Cobbs AI,
Prakash R,
Li W,
Pillai B,
Hafez S,
Coucha M,
Johnson MH,
Ogbi SN,
Fagan SC,
Ergul A. Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes. Am J Physiol Heart Circ Physiol 2013; 304(6): H806-15.
[11]
Furfaro AL,
Sanguineti R,
Storace D,
Monacelli F,
Puzzo A,
Pronzato MA,
Odetti P,
Traverso N. Metalloproteinases and advanced glycation end products: coupled navigation in atherosclerotic plaque pathophysiology?
Exp Clin Endocrinol Diabetes 2012; 120(10): 586-90.
[13]
Symeonidis C,
Papakonstantinou E,
Galli A,
Tsinopoulos I,
Mataftsi A,
Batzios S,
Dimitrakos SA. Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes.
Graefes Arch Clin Exp Ophthalmol 2013; 251(3): 741-9.
[14]
Chung AW,
Hsiang YN,
Matzke LA,
McManus BM,
van Breemen C,
Okon EB. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature.
Circ Res 2006; 99(2): 140-8.
[15]
Lee SW,
Song KE,
Shin DS,
Ahn SM,
Ha ES,
Kim DJ,
Nam MS,
Lee KW. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Diabetes Res Clin Pract 2005; 69(2): 175-9.
[16]
Meissburger B,
Stachorski L,
Röder E,
Rudofsky G,
Wolfrum C. Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans.
Diabetologia ; 54(6): 1468-79.
[17] Sharma A, Vijayakumar M, Rao ChV. Action of Portulaca oleracea against stereptozotocin-induced oxidative stress in experimental diabetic rats. J Complement Integrat Med 2009; 6(1): 1-10.
[18]
Lee AS,
Lee YJ,
Lee SM,
Yoon JJ,
Kim JS,
Kang DG,
Lee HS. An aqueous extract of Portulaca oleracea ameliorates diabetic nephropathy through suppression of renal fibrosis and inflammation in diabetic db/db mice. Am J Chin Med 2012; 40(3): 495-510.
[19]
Chan K,
Islam MW,
Kamil M,
Radhakrishnan R,
Zakaria MN,
Habibullah M,
Attas A. The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak.
J Ethnopharmacol 2000; 73(3): 445-51.
[20] Sun XY, Liu N, Chen B, Meng XJ. The study on antioxidation property of flavonoids from portulaca oleracea L. Shenyang Agric Univ 2006: 37: 108-9.
[21] Xin HL, Xu YF, Yue XQ, Hou YH, Li M, Ling CQ. Analysis of Chemical Constituents in Extract from Portulaca oleracea L. with GC-MS Method (In Chinese). Pharmaceut J Chin People’s Liberat Army 2008; 24: 133-6.
[22]
El-Sayed MI. Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy.
J Ethnopharmacol 2011; 137(1): 643-51.
[23]
Kim SH,
Hong SB,
Suh YJ,
Choi YJ,
Nam M,
Lee HW,
Park IeB,
Chon S,
Woo JT,
Baik SH,
Park Y,
Kim DJ,
Lee KW,
Kim YS;
KNDP Study Group. Association between nutrient intake and obesity in type 2 diabetic patients from the Korean National Diabetes Program: a cross-sectional study.
J Korean Med Sci 2012; 27(10): 1188-95.
[24]
Rogowicz A,
Zozulińska D,
Wierusz-Wysocka B. The role of matrix metalloproteinases in the development of vascular complications of diabetes mellitus--clinical implications.
Pol Arch Med Wewn 2007; 117(3): 43-8.
[25]
Signorelli SS,
Malaponte G,
Libra M,
Di Pino L,
Celotta G,
Bevelacqua V,
Petrina M,
Nicotra GS,
Indelicato M,
Navolanic PM,
Pennisi G,
Mazzarino MC. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease.
Vasc Med 2005; 10(1): 1-6.
[26] Mohajerani A, Ghahari A, Larijani B. Investigate the role of MMPs and 14-3-3 protein in diabetes create and complication. Iranian Journal Diabetes and Lipid Disorders 2011; 10(6): 585-600.
[27]
Ruel G,
Pomerleau S,
Couture P,
Lemieux S,
Lamarche B,
Couillard C. Plasma matrix metalloproteinase (MMP)-9 levels are reduced following low-calorie cranberry juice supplementation in men.
J Am Coll Nutr 2009; 28(6): 694-701.
[28]
Lee AS,
Lee YJ,
Lee SM,
Yoon JJ,
Kim JS,
Kang DG,
Lee HS. Portulaca oleracea Ameliorates Diabetic Vascular Inflammation and Endothelial Dysfunction in db/db Mice.
Evid Based Complement Alternat Med 2012; 2012: 741824.
[29]
Laitiff AA,
Teoh SL,
Das S. Wound healing in diabetes mellitus: traditional treatment modalities.
Clin Ter 2010; 161(4): 359-64.
[30]
Chen B,
Zhou H,
Zhao W,
Zhou W,
Yuan Q,
Yang G. Effects of aqueous extract of Portulaca oleracea L. on oxidative stress and liver, spleen leptin, PARα and FAS mRNA expression in high-fat diet induced mice.
Mol Biol Rep 2012; 39(8): 7981-8.
[31]
Gong F,
Li F,
Zhang L,
Li J,
Zhang Z,
Wang G. Hypoglycemic effects of crude polysaccharide from purslane.
Int J Mol Sci 2009; 10(3): 880-8.
Pathobiology Reserach